Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Gerresheimer Expecting 4% to 6% Revenue Growth in Medium Term


News provided by

Gerresheimer AG

Oct 08, 2014, 15:23 ET

Share this article

Share toX

Share this article

Share toX

  • Gerresheimer sees good growth opportunities in long-term megatrends of pharma and healthcare 
  • Growing importance of drug delivery and dosage devices in Western markets and of pharmaceutical primary packaging business in emerging markets 
  • Mid-term growth potential 2016 to 2018: 4% to 6% average organic revenue growth and up to 21% adjusted EBITDA margin 
  • Initial indications for financial year 2015: around 1% to 3% organic revenue growth and up to EUR 10m higher adjusted EBITDA 

- Cross reference: The full press release is available at: http://www.presseportal.de/dokumente -

DUSSELDORF and BUNDE, Germany, Oct. 8, 2014 /CNW/ - Gerresheimer AG set out its strategy at a Capital Markets Day held in Bünde, Westphalia. "Health and well-being are issues taking on ever greater global significance. I believe we have very strong medium-term growth prospects with our products becoming increasingly important. We are outstandingly well placed with our broad product portfolio, experience and proximity to the customer. We aim to grow in promising pharma markets, develop innovative products for safe and simple drug delivery and expand local production in the main emerging economies," explained Uwe Röhrhoff, CEO of Gerresheimer AG, speaking to investors and analysts. "We will invest heavily in production capacity as well as in standardizing our technologies and in quality systems. This is the basis for healthy medium-term growth for our Company."

CEO Röhrhoff took investors and analysts through key trends in the growing pharma markets and charted Gerresheimer's plans for successful growth based on those trends. "The pharma and healthcare markets offer attractive prospects and are growing continually. Our strategy for profitable growth is in place and we are successful both with our high-quality glass and plastic pharmaceutical primary packaging and with complex products like insulin pens, inhalers, autoinjectors and prefillable syringes. I am very optimistic for the future of our Company," Röhrhoff said.

Medium-term outlook and initial indications for 2015 

Gerresheimer reaffirmed its medium-term guidance for revenue growth at the Capital Markets Day. For the years 2016 to 2018, the Company expects average annual organic revenue growth of some 4% to 6% at constant exchange rates. Alongside this, the Company held out the prospect of an adjusted EBITDA margin of up to 21% in the same period. Capital expenditure is expected to be around 9% to 10% of revenues.

Gerresheimer also gave initial indications for financial year 2015, to be followed up with more precise figures in February 2015 on presentation of the 2014 annual financial statements. The Company plans to streamline its portfolio in 2015. It will continue standardizing to trim costs. Further investment in capacity expansion is also on the agenda for the US, India and the Czech Republic. On a very preliminary estimate, Gerresheimer anticipates organic revenue growth of around 1% to 3% at constant exchange rates in the financial year 2015. With regard to earnings, Gerresheimer expects adjusted EBITDA to climb by up to EUR 10m in 2015. Capital expenditure is expected to be around 9% to 10% of revenues at constant exchange rates.

Key trends for tomorrow's pharma market 

The Company eyes six key trends for the future of pharma markets:

  • Patents on numerous drugs are expiring at the same time as generic drugs gain ground.
  • More people in emerging markets have access to healthcare and hence to medication.
  • Regulatory requirements relating to drugs are increasing globally. This is already evident today in stricter regulation by US health authorities.
  • New drugs are emerging, many of them biotech-based, with special requirements in terms of administration and packaging.
  • Chronic diseases such as asthma and diabetes are on the increase worldwide.
  • There is a growing trend toward self-medication by patients.

Success strategy for the Plastics & Devices Division 

Based on the key healthcare market trends, Gerresheimer is forging ahead with its strategy for its two main divisions. In the Plastics & Devices Division, Gerresheimer develops and produces complex, customer-specific products for safe and simple drug delivery and dosage, including pens, inhalers and prefillable glass syringes. There is notable growth in demand for these products in Europe and North America, where Gerresheimer holds a strong position (number one or two) in each submarket it serves. The Company is adding to production capacity and expanding global development centers for such products. In prefillable syringes, the Company sets new standards of quality and flexibility with its very latest, fourth production line in its global Syringe Competence Center in Bünde, Germany. Other innovations in this sector relate to new materials, such as sophisticated plastics like COP, suitable as an alternative for some drug packaging products. The Company also gave a heads-up insight into its project pipeline for medical plastic systems. In the plastic drug packaging product category, Gerresheimer targets innovations in closures, caps and dosage systems along with growth in South American and Asian emerging economies, where it has several plants.

Success strategy for the Primary Packaging Glass Division 

In its second major division, Gerresheimer produces glass primary packaging items such as injection vials, ampoules, cartridges and pharma bottles. Here, too, it holds strong, number one or number two positions with a broad product range in the European, North American and emerging markets. In light of increasing regulatory requirements for drugs and drug packaging, Gerresheimer's strategy consists in further improving quality as well as continuing to standardize technologies and production processes across all plants worldwide. In terms of upcoming investment to expand production, the priority is on Asia and above all India. While glass is the oldest and still remains unbeaten as the best material for safe, long-term packaging and transportation of pharmaceuticals, this is nonetheless another area where Gerresheimer continues to push the innovation envelope. As a case in point, the Company is working on innovations in the manufacture of glass used in pharmaceutical applications.

Producing sophisticated cosmetic glass is a good supplementary business in this division. Key factors here include extended capabilities in glass processing and decoration. Here, Gerresheimer is outstandingly well placed for the future, notably in the European cosmetics market, with a broad range of innovative products and finishing technologies.

The full Capital Markets Day strategy presentation and the recorded webcast are available online at http://www.gerresheimer.com/en/investor-relations/

The third quarter 2014 press release is available here:

http://www.gerresheimer.com/nc/en/news-events/press-releases/corporate-news

The Interim Report is available at:

http://www.gerresheimer.com/en/investor-relations/reports

SOURCE: Gerresheimer AG

Gerresheimer AG, Klaus-Bungert-Strasse 4, 40468 Duesseldorf, Germany; Jens Kürten, Director Corporate Communication & Marketing, Phone: +49-211-6181-250, Fax: +49-211-6181-241, E-Mail: [email protected], Internet: http://www.gerresheimer.com

Modal title

Organization Profile

Gerresheimer AG

    Also from this source

  • Centor Launches Smart Pill Organizer to Support Medication Adherence

  • Gerresheimer: FDA grants Tentative Approval of SQ Innovation's Lasix® ONYU*

  • Gerresheimer expands capacities for Medical Systems in the USA

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.